-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compilenewborn
Recently, Moderna announced positive interim data from the Phase 2/3 KidCOVE study of its COVID-19 vaccine (mRNA-1273)
Based on these data, Moderna will submit a license application in the coming weeks to the U.
KidCOVE is a randomized, observer-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of two doses of mRNA-1273, 28 days apart, in a population of healthy children
Data are reported for the age groups 6 months to under 2 years and 2 years to under 6 years
In these 2 age groups, the immunogenicity of the two-dose 25-µg immunization was similar to that of the 100-µg two-dose immunization in adults 18 to 25 years old, meeting noninferiority criteria and immune bridging, indicating that mRNA-1273 was 18-25 The benefits for adults as young as 6 months are also available to children and infants as young as 6 months old
During the KidCOVE study in these young populations, the Omicron variant of SARS-CoV-2 was circulating in the United States
Similar to adults, Moderna is preparing to evaluate the potential of the mRNA-1273 vaccine booster in all pediatric populations, including 6 months to <6 years, 6 to <12 years, and adolescents
Reference source: Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint
